Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (41-50 of 219) with videos related to

Pageof 22
Sort By:
Journal of Drugs in Dermatology : JDD|March 26, 2019
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque PsoriasisLeon H. Kircik, Kim A. Papp, Linda Stein Gold, et al.
The Journal of Dermatological Treatment|July 25, 2022
Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasisKim A Papp, Henrik Thoning, Sascha Gerdes, et al.
Journal of Cutaneous Medicine and Surgery|June 21, 2012
Biologic therapy in psoriasis: perspectives on associated risks and patient managementKim A Papp, Joel Dekoven, Laurie Parsons, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 7, 2018
Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized TrialsKim A Papp, Min Yang, Murali Sundaram, et al.
Journal of Cutaneous Medicine and Surgery|April 25, 2006
Strategies for optimizing treatment with efalizumab in moderate to severe psoriasisKim A Papp, Vincent Ho, Richard Langley, et al.
Dermatology and Therapy|October 21, 2022
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical TrialsJonathan I Silverberg, Mark Boguniewicz, Jon Hanifin, et al.
The New England Journal of Medicine|October 28, 2011
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasisKristian Reich, Richard G Langley, Kim A Papp, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasisKim A Papp, Bruce Miller, Kenneth B Gordon, et al.
Clinical Drug Investigation|October 12, 2010
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trialsKim A Papp, James Signorovitch, Karthik Ramakrishnan, et al.
Cutis|December 2, 2024
Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque PsoriasisApril W Armstrong, Robert Bissonnette, Raj Chovatiya, et al.
Pageof 22

Showing results (41-50 of 219) with videos related to

Sort By:
Pageof 22
Journal of Drugs in Dermatology : JDD|March 26, 2019
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque PsoriasisLeon H. Kircik, Kim A. Papp, Linda Stein Gold, et al.
The Journal of Dermatological Treatment|July 25, 2022
Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasisKim A Papp, Henrik Thoning, Sascha Gerdes, et al.
Journal of Cutaneous Medicine and Surgery|June 21, 2012
Biologic therapy in psoriasis: perspectives on associated risks and patient managementKim A Papp, Joel Dekoven, Laurie Parsons, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 7, 2018
Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized TrialsKim A Papp, Min Yang, Murali Sundaram, et al.
Journal of Cutaneous Medicine and Surgery|April 25, 2006
Strategies for optimizing treatment with efalizumab in moderate to severe psoriasisKim A Papp, Vincent Ho, Richard Langley, et al.
Dermatology and Therapy|October 21, 2022
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis is Efficacious Regardless of Age of Disease Onset: a Post Hoc Analysis of Two Phase 3 Clinical TrialsJonathan I Silverberg, Mark Boguniewicz, Jon Hanifin, et al.
The New England Journal of Medicine|October 28, 2011
A 52-week trial comparing briakinumab with methotrexate in patients with psoriasisKristian Reich, Richard G Langley, Kim A Papp, et al.
Journal of the American Academy of Dermatology|February 21, 2006
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasisKim A Papp, Bruce Miller, Kenneth B Gordon, et al.
Clinical Drug Investigation|October 12, 2010
Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trialsKim A Papp, James Signorovitch, Karthik Ramakrishnan, et al.
Cutis|December 2, 2024
Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque PsoriasisApril W Armstrong, Robert Bissonnette, Raj Chovatiya, et al.
Pageof 22